This unique mechanism makes it one of the most promising compounds for comprehensive metabolic regulation, supporting blood sugar balance, appetite suppression, fat loss, and potential lean muscle preservation
Liraglutide, semaglutide, and tirzepatide are all GLP-1 agonists resulting in significant weight loss in RCTs
During dose increases, keeping the same weekly injection day is criticalthis helps your body adapt smoothly and makes it easy to track whether hunger returns or side effects change
The phase 3 program is studying maintenance doses of 4 mg, 9 mg, or 12 mg
This often leads to reduced calorie intake
In addition, other patient-specific treatment strategies tailoring the use of GLP-1 RAs and other options to the HF phenotype and stage are likely also valuable to study and validate